Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs MMF in Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of obinutuzumab in Idiopathic nephrotic syndrome (INS), sponsored by Roche. Started Mar 2023; status: completed.
02
Drugs
obinutuzumab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT05627557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627557.